featured-image

Dupilumab is a human monoclonal antibody that blocks the receptor shared by interleukin-4 (IL-4) and IL-13, both of which are key to the development of type 2 inflammation in chronic obstructive pulmonary disease (COPD). A recent study published in The New England Journal of Medicine discusses the results of a second phase III trial on dupilumab in a subset of COPD patients. Study: Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation.

Image Credit: Wildflower_macro / Shutterstock.com COPD is a progressive lung condition that is associated with high morbidity and mortality. Although it is a chronic condition, COPD is marked by exacerbations that may lead to more rapid clinical progression.



Current care for COPD patients often involves triple inhaler therapy that comprises a glucocorticoid, long-acting muscarinic antagonist (LAMA), and long-acting beta-agonist (LABA). Despite the availability of this treatment, many COPD patients are still at a 50% risk of exacerbations. Therefore, there remains an urgent need for more effective COPD therapies to prevent these events, as well as achieve better lung function in these patients to ultimately improve their quality of life.

The NOTUS RCT was a multi-nation multicenter study sponsored by Regeneron and Sanofi. The current study was designed to evaluate the efficacy of dupilumab over a 52-week period in symptomatic COPD patients with increased eosinophil counts, which is indicative of chronic type 2 inflammation. Al.

Back to Health Page